[Possibilities of medical treatment in acromegaly].
Active acromegaly deteriorates the quality of life and shortens the life expectancy. Surgery is the first-line therapy in the majority of patients, followed by radiotherapy in unsuccessful cases. The surgery cure rate is only one half in the case of macroadenomas and it takes years before radiotherapy normalizes GH and IGF-I levels. In the interim, medical therapy is necessary. Second-generation dopamine agonists (cabergoline) are successful in about one third of patients, especially in those with lower basal IGF-I levels and with adenomas co-secreting prolactin. Somatostatin analogues octreotide and lanreotide are the gold standard of medical treatment - both are available in a form applicable as once-monthly injections. They successfully control disease activity in the majority of patients and induce tumour shrinkage in part of adenomas. Surgical debunking of macroadenomas improves the results of therapy with somatostatin analogues and it is not necessary to discontinue this therapy before radiotherapy. The potential of higher efficiency represent new analogues, binding not only to somatostatin receptor subtype 2, but also to subtype 5 and "dopastatins" that are able to bind both to the somatostatin and the dopamine D2 receptors. The advent of the GH receptor antagonist pegvisomant provides the possibility to normalise IGF-I in virtually every patient. Combined treatment with somatostatin analogues probably enables reduction from daily to weekly injections.
Cáp
J
J
II. interní klinika LF UK a FN, Hradec Králové. capj@lfhk.cuni.cz
Nemecek
S
S
Rezácová
M
M
Cerman
J
J
D000172:Acromegaly / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use; D013006:Growth Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018491:Dopamine Agonists; D013004:Somatostatin; D013006:Growth Hormone